Navigation Links
Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology
Date:4/14/2008

ty to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons play ... key link between the medical device industry and key ... in the coming years as the device industry relies ... According to research by benchmarking firm, Best Practices, LLC, ... an important edge is by harnessing new technology to ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... September 2 , - CAPRA-2-Data ... Nitec Pharma AG ("Nitec" or "Nitec ... commercialization of,medicines to treat chronic inflammation and pain-related diseases, today,announced ... its,lead product, Lodotra(TM). , The CAPRA-2 ...
... , , , ... Park, Ph. D., Head of Process Sciences at aTyr Pharma, a ... newly emerging class of natural biotherapeutics, will be a featured speaker ... will present his talk "Selecting the Optimal Biotherapeutic Candidate for Development" ...
Cached Medicine Technology:Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA 2Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA 3Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 2
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... BRUNSWICK, N.J., March 13 Johnson &,Johnson will ... Health Care,Conference on Thursday, March 20th at the ... Goggins, Worldwide Chairman,Consumer Group will represent the Company ... The webcast will be available to investors ...
... found 10 percent fewer new cases over a decade , , THURSDAY, ... every other day seems to reduce the risk of developing asthma ... of Thorax , essentially mirrors a similar study in which ... the study authors warned that the research was still not ...
... 51, Scores Big at Arnold Classic; Says ... Better, Faster -, PHOENIX, March 13 NutraCea ... bran (SRB), nutrient,research and technology announced today that champion ... (IPF) world,record with a squat lift of 716 pounds ...
... Owing to Safety and Delivery End Points, Drugs from Eli ... According ... from Decision Resources, WALTHAM, Mass., March 13 Decision ... on pharmaceutical and,healthcare issues, finds that a drug,s effect on ...
... FRANCISCO, Calif., March 13 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... chairman and chief executive officer, is scheduled to present,a ... Healthcare,Conference in Miami, Florida on Tuesday, March 18 at ... to participate in a panel discussion titled,"Biotech Models: Should ...
... Neurochem,(International) Limited (Neurochem), a wholly-owned subsidiary of ... announces that the Company is taking new,initiatives ... its investigational,product candidate, eprodisate (KIACTA(TM)), to obtain ... (AA) amyloidosis. Neurochem,s decision to build,upon its ...
Cached Medicine News:Health News:Aspirin Reduces Asthma Risk Among Older Women 2Health News:New World Record Holder in Powerlifting Credits NutraCea's Unique Rice-Bran-derived Product as his 'Secret Weapon' 2Health News:New World Record Holder in Powerlifting Credits NutraCea's Unique Rice-Bran-derived Product as his 'Secret Weapon' 3Health News:New World Record Holder in Powerlifting Credits NutraCea's Unique Rice-Bran-derived Product as his 'Secret Weapon' 4Health News:Current and Emerging Therapies Have No Advantage Over Pfizer's Lyrica in Their Effect on Patients' Quality of Life in the Treatment of Diabetic Neuropathy 2Health News:Rigel Announces Participation in Upcoming Investor and Partnering Conferences 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4
... Keratometer now utilizes LED technology ... removing the need to ever ... change are all the great ... Keratometer the worldwide instrument of ...
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
For presumptive identification of E. coli serogroup O157:H7 cultured on laboratory media....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: